NEW YORK, USA AND ABU DHABI, UAE, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Sherlocq, the first AI-native regulatory intelligence platform for global financial services, today announced its public launch. Designed for compliance officers, lawyers, risk professionals, and regulators who operate at the intersection of law, governance, and institutional accountability, Sherlocq delivers regulatory intelligence that is precise, traceable, and usable at institutional scale.The launch marks the emergence of a new category in enterprise AI: regulatory intelligence, a vertical distinct from generic AI assistants, conventional regtech monitoring tools, and document management platforms. Sherlocq has been built from the ground up to meet the security, privacy, and domain standards that regulated institutions require, and which no general-purpose AI platform has been designed to deliver.THE PROBLEMFinancial institutions, law firms, regulators, and consultants collectively spend over $300 billion every year on regulatory compliance. More than ten million professionals carry the weight of that complexity daily, tracking regulatory changes across dozens of jurisdictions, reviewing thousands of documents, and making high-stakes decisions that can determine the fate of institutions and individuals alike.Until now, the tools available have been fundamentally inadequate: monitoring without interpretation, alerts without answers, search without synthesis. Regulatory research has remained a largely manual process for decades. Vertical AI has already demonstrated category-defining value in adjacent domains. Regulatory intelligence represents a larger, more global, and more complex opportunity.Sherlocq changes that.THE PLATFORMAt launch, Sherlocq covers the regulatory output of governments, supervisory authorities, and enforcement bodies across 30+ jurisdictions, including the US, UK, UAE, Singapore, and Hong Kong. It ingests, structures, and indexes this information continuously, so when a compliance officer, lawyer, or risk professional asks a question, Sherlocq returns a precise, sourced, and traceable answer in seconds. Research that previously required hours of manual work across multiple sources is completed in under a minute.The platform launches with three live capabilities:Regulatory Research and Analysis - Multi-jurisdiction research, cross-border regulatory comparison, compliance framework analysis, and obligation mapping across the full spectrum of financial services regulation, covering all major regulated financial centres.Document Intelligence - Structured review, gap assessment, benchmarking, and policy analysis against applicable regulatory standards, available on the native Sherlocq platform.Sanctions Intelligence - Real-time, multi-regime sanctions research across OFAC, OFSI, EU, UAE, and 320+ data sources in a single query, with full source traceability. The first AI-native platform to deliver this level of depth and auditability across multiple sanctions regimes simultaneously.Sherlocq is available on web, iOS, and Android, for individual professionals and enterprise organisations. AI connectors are live for Claude and ChatGPT, enabling regulatory research to be accessed directly within the tools professionals already use. Microsoft Copilot and Google Gemini integrations follow shortly.Sherlocq is certified to ISO 27001 and ISO 27701 standards, meeting the security and data privacy requirements of regulated financial institutions globally.FOUNDER'S STATEMENT"I have spent my career sitting across the table from regulators, leading investigations at the highest levels, and advising institutions in the most consequential moments of their existence. In every one of those engagements, the same problem recurred: brilliant professionals, at world-class institutions, spending most of their time on research and cross-referencing that should have been automated years ago. Not because the technology did not exist. Because no one had built it with the rigour, the domain depth, and the institutional trust that this work demands. That is what we built. Sherlocq is not a general AI tool adapted for compliance. It is the intelligence infrastructure that this industry has always needed and never had," said Bhavin Shah, Founder and Chief Executive Officer, Sherlocq.ABOUT THE FOUNDERBhavin Shah is a globally recognised regulatory and compliance leader with over twenty years of experience advising sovereigns, regulators, boards, and financial institutions across their most complex and politically sensitive challenges. His career spans multi-jurisdiction investigations, AML and financial crime reform, regulatory negotiations, crisis management, and governance advisory across the US, UK, Middle East, and Asia Pacific. He has advised some of the world's most consequential regulatory reform processes and financial institutions at moments of institutional stress, enforcement risk, and strategic transformation.Shah is a World Economic Forum Young Global Leader (2020), a board member of the D2A2 digital assets and AI policy forum, and holds executive education credentials from Harvard Business School and Harvard Kennedy School. He serves as an independent non-executive director on the boards of regulated financial institutions, giving him direct and ongoing insight into the governance, compliance, and regulatory pressures that Sherlocq is designed to address.INDUSTRY VOICES"Regulatory complexity has been accelerating for years and this is only compounding with the recent trends toward fragmentation around the globe. The tools available to compliance professionals have not kept pace. Sherlocq addresses that gap in a way that is substantive, not superficial. What distinguishes this platform is that it has been built with a genuine understanding of how regulated institutions work and what they actually need to be more effective and more efficient. The depth, the traceability, and the institutional-grade approach reflect the kind of rigour that regulators and boards rightly expect. I am proud to support Bhavin and the Sherlocq team as they bring this important product to market," said Bryan Stirewalt, Former Chief Executive, Dubai Financial Services Authority; Former National Bank Examiner, Office of the Comptroller of the Currency; Board Advisor, Sherlocq."Running a banking group across more than 35 markets meant living with regulatory complexity as a daily operational reality. Our teams were talented and diligent but the tools available forced them into a process that was slow, fragmented and heavily manual. Sherlocq solves that problem. It gives compliance and legal professionals the structured multi-jurisdictional intelligence that I would have wanted for my team. This is the platform the industry has always needed,” said Arnold Ekpe, Former Group Chief Executive Officer, Ecobank Group; Board Advisor, Sherlocq.ABOUT SHERLOCQSherlocq Inc. is a US-incorporated AI technology company (Delaware) with principal offices in New York and Abu Dhabi, UAE, and the creator of the first AI-native regulatory intelligence platform purpose-built for global financial services. The company has completed a pre-seed financing round backed by investors across the US, UAE, and Europe. Designed for compliance officers, lawyers, risk professionals, regulators, and governance teams, the platform delivers multi-jurisdiction regulatory research, document intelligence, and sanctions intelligence, with workflow automation and deeper enterprise capabilities on the near-term roadmap. Sherlocq is certified to ISO 27001 and ISO 27701 standards and is available globally on web, iOS, and Android. Financial institutions, law firms, and professional services organisations seeking enterprise access are invited to contact hello@sherlocq.com. sherlocq.com | sherlocq.ai | hello@sherlocq.com MEDIA CONTACTFor media enquiries, interview requests with Bhavin Shah, or access to additional materials including product demonstrations, founder biography, and platform assets:Press contact: press@sherlocq.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BILLUND, DENMARK, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - At the LEGO Foundation's annual meeting, the Board of Directors elected Agnete Kirk Kristiansen as Chair of the Board. As fourth generation member of the Kirk Kristiansen family, owners of the LEGO Group, she becomes only the fifth Chair of the Foundation since it was founded in 1986.Agnete Kirk Kristiansen has served as Deputy Chair of the LEGO Foundation since 2023 and replaces her brother Thomas Kirk Kristiansen who steps down to assume the position of Deputy Chair. In addition to her role at the LEGO Foundation, Agnete Kirk Kristiansen also serves as Deputy Chair of KIRKBI A/S, the family-owned holding and investment company that owns 75% of the LEGO Group.As ascending Chair, Agnete Kirk Kristiansen highlighted the role of the LEGO Foundation in building a brighter tomorrow for children around the world:I am truly honored to step into the role as Chair of the LEGO Foundation and to continue our important work for children. The foundation holds a very special place in our family and has done so ever since it was established more than 40 years ago. A deep sense of responsibility to make a positive difference for children runs through our family and I strongly believe that every child should have the opportunity to thrive and grow. I am proud to contribute to this mission and help carry it forward.The change in chair takes place the year after Agnete stepped into the role as chair of non-profit foundation Ole Kirk's Fond. With the transition, the fourth generation of the owner family is broadening its engagement and commitment to active ownership.Descending Chair Thomas Kirk Kristiansen said:It has been a privilege to chair the LEGO Foundation for the past 10 years, and I am very happy to now pass on the role to Agnete. She is deeply committed to the LEGO Foundation mission, and I know she will do her utmost to further the cause of securing a childhood for all. During her tenure as Deputy Chair, she has played an integral part in shaping the foundation's current strategy and as she steps into the role as Chair, we further widen the active ownership and engagement from the family across the LEGO ecosystem.Thomas Kirk Kristiansen has served as Chair of the LEGO Foundation since 2016 and in that period the foundation has committed grants of more than DKK 15 billion (EUR 2 billion) through partner organisations across the globe to improve children's outcomes.For 40 years, the LEGO Foundation has been focused on giving back and building a better world for children. We are very mindful of the trust families and communities place in us, and it is not a responsibility we take lightly. Even in the most challenging settings, the foundation can help put a smile on a child's face, lift up learners of all abilities and change life paths. We do so with the utmost sensitivity and responsibility, said Agnete Kirk Kristiansen.In addition to safeguarding the continued development and success of the LEGO Group as part-owner, the LEGO Foundation pursues its philanthropic mission to support initiatives within education, research, and child development through funding of and close collaboration with organisations such as Brac, IRC, UNICEF, Save the Children, Norwegian Refugee Council and others.Further changes to the LEGO Foundation BoardIn addition to Agnete and Thomas Kirk Kristiansen changing roles as Chair and Deputy Chair, the LEGO Foundation Board of Directors at its May meeting also elected as member of the Board Ingrid Stange, who brings a wealth of experience in philanthropy, education and non-profit leadership. Further, both Jørgen Vig Knudstorp, former CEO of the LEGO Group, and El Hadji Amadou Gueye Sy (As), former Secretary-General of the International Federation of Red Cross and Red Crescent Societies, left the Board after 16 and four years of service respectively to the LEGO Foundation.Thomas Kirk Kristiansen thanked the two departing Board members for their long-standing commitment to the foundation:We look very much forward to welcoming Ingrid, who brings highly complementary expertise to the board. At the same time, I thank As for bringing invaluable insights and experience to help shape our work.I would also like to extend my sincerest gratitude to Jørgen for his unwavering dedication to the foundation. During his extensive tenure, Jørgen has been instrumental in defining our vision and strategy while never losing sight of the children we are here to serve.Additionally, Malou Aamund, who has served on the Board since 2021, stepped into the role of Second Deputy Chair of the Foundation.Biography: Agnete Kirk KristiansenLEGO Foundation2026 - Chair of the Board of Directors2023 - 2026 Second Deputy Chair of the Board of DirectorsFrom 2008 Member of the Board of DirectorsKIRKBI A/S2024 - Deputy Chair of the BoardCentre for ADHD+, Aarhus, DenmarkFounderOle Kirk's Fond2025 - Chair of the BoardDegreePsychology, Aarhus University, 2010Additional roles, present and past:Executive Manager, KIRK83 Holding ApSMember of the Advisory Board, RucaRepresentative of the fourth generation of the LEGO owner familyExtensive experience in family-owned companies, long-term stewardship and board workLEGO Foundation Board of DirectorsAgnete Kirk Kristiansen - ChairThomas Kirk Kristiansen - First Deputy ChairMalou Aamund - Second Deputy ChairHilary Pennington - Member of the BoardIngrid Stange - Member of the BoardLEGO Foundation Board of Directors Chairs1986 - 1993: Gotfred Kirk Kristiansen (2nd-generation LEGO owner)1993 - 2000: Bent Skov2000 - 2016: Kjeld Kirk Kristiansen (3rd-generation LEGO owner)2016 - 2026: Thomas Kirk Kristiansen (4th-generation LEGO owner)2026 - Agnete Kirk Kristiansen (4th-generation LEGO owner)About LEGO Fonden:The LEGO Foundation is a Danish corporate foundation entrusted with 25 % ownership of the LEGO Group. The Foundation works with partners around the world to support children's needs and champion the dignity of childhood. Through both philanthropic donations and impact investments the Foundation exists to build the conditions and create the space for every child, everywhere, to thrive and grow. More information about the LEGO Foundation can be found at: https://www.legofoundation.com/Contact information:Mads Hvitved Grandmads.hvitved.grand@legofoundation.comSOURCE: LEGO Fonden Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Highlights:According to third-party industry reports, the U.S. RPM market is currently $14 Billion alone and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models¹Pilot initiative launched across multiple provider offices focused on chronic care management (CCM) and remote patient monitoring (RPM) through it's MSO infrastructureApproximately 1,500+ claims generated to date through the pilot infrastructure with expansion roadmap targeting additional providersWellgistics Pharmacy Network of 6,500+ independent pharmacies positioned to support patient engagement and care coordination initiativesParticipating pharmacists expected to gain access to new clinical service revenue opportunitiesTAMPA, FLA., May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced a pilot collaboration with Kare PharmTech and Kare Clinicals integrating its MSO infrastructure to support chronic care management ("CCM") and remote patient monitoring ("RPM") services across participating provider offices. According to third-party industry reports, the U.S. RPM market is currently $14 Billion and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models.¹The pilot program currently includes multiple provider offices, with Kare Clinicals MSO serving as the billing provider on behalf of participating offices and rendering providers. The initiative is designed to support patient engagement, care coordination, and longitudinal monitoring programs through scalable operational and technology-enabled workflows. All CCM and RPM services are expected to be furnished and billed by appropriately licensed providers and participating entities in accordance with applicable federal and state healthcare laws, reimbursement requirements, and payor program rules.The companies stated that the pilot infrastructure has already generated 1,500+ claims and is intended to serve as the foundation for broader expansion efforts targeting approximately additional providers over time. As part of the collaboration, Wellgistics Health intends to leverage its network of more than 6,500 independent pharmacies to help identify and support eligible patients who may benefit from CCM and RPM services. Participating pharmacies within the Wellgistics Pharmacy Network may also have opportunities to participate in clinical engagement initiatives associated with the program.Prashant Patel, President and CEO of Wellgistics Health, Inc., stated, "We believe the convergence of pharmacy engagement, provider connectivity, and technology-enabled care coordination represents a significant opportunity to improve patient outcomes while creating new economic opportunities for independent pharmacies. Through this pilot collaboration with Kare PharmTech, we are establishing infrastructure designed to support scalable patient engagement models across chronic care management and remote patient monitoring programs."Mital Panera, Founder and Chief Executive Officer of Kare PharmTech, added, "Our focus has been on building an operationally efficient MSO platform capable of supporting providers with care coordination and reimbursement workflows. By collaborating with Wellgistics Health and its pharmacy network, we believe we can further expand patient participation, improve continuity of care, and create a scalable framework for future provider growth."The companies noted that the pilot program remains subject to ongoing operational development, provider participation, and regulatory compliance considerations as expansion efforts continue.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.About Kare PharmTech, LLCKare Clinicals is part of the larger ecosystem of companies owned by Kare PharmTech, LLC, a company controlled by Dr. Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for $200 million. In 2007, Dr. Patel founded America's 1st Choice Holdings and acquired Freedom Health and Optimum Holdings. In 2017, he sold America's 1st Choice Holdings to Anthem, Inc. Dr. Patel is a noted philanthropist and was named Floridian of the Year by Florida Trend Magazine.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's expectations, beliefs, plans, objectives, intentions, strategies, future events, or performance, including statements regarding the potential benefits, scalability, expansion, commercialization, provider participation, reimbursement opportunities, patient engagement initiatives, operational capabilities, and future development of the pilot collaboration with Kare PharmTech and Kare Clinicals, as well as the anticipated role of the Wellgistics Pharmacy Network in supporting CCM and RPM initiatives. Words such as "anticipate," "believe," "could," "expect," "intend," "may," "plan," "potential," "project," "seek," "should," "will," and similar expressions are intended to identify forward-looking statements.These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, without limitation, risks relating to provider adoption and participation, reimbursement outcomes, patient engagement levels, operational execution, scalability of the pilot program, regulatory and healthcare compliance considerations, changes in applicable laws or reimbursement policies, market acceptance of the Company's services, competitive factors, and the Company's ability to develop and maintain strategic relationships and successfully implement its business strategy.The pilot collaboration described in this press release is exploratory in nature, and there can be no assurance that the initiative will result in expanded commercial relationships, material revenue opportunities, or long-term operational success.Additional information regarding these and other risks can be found in the Company's filings with the U.S. Securities and Exchange Commission, including the risk factors contained therein. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.Wellgistics Media & Investor ContactMedia: media@wellgisticshealth.comInvestor Relations: IR@wellgisticshealth.com[1] MarketsandMarkets - U.S. Remote Patient Monitoring Market ReportSOURCE: Wellgistics Health, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

重點摘要：· 根據第三方產業報告，隨著醫療服務提供者持續轉向價值導向及居家照護模式，美國遠端病患監測（RPM）市場目前規模已達 140 億美元，預計到 2030 年將成長至約 290 億美元，年複合成長率（CAGR）為 12.6%¹· 透過其醫療服務組織（MSO）基礎設施，於多家醫療機構啟動試點計畫，專注於慢性病管理（CCM）及遠距病患監測（RPM）· 迄今透過此試點基礎設施已產生逾1,500筆理賠，且擴展藍圖目標涵蓋更多醫療服務提供者· Wellgistics 藥局網絡擁有超過6,500家獨立藥局，具備支援患者參與及照護協調計畫的優勢· 參與的藥師預期將獲得新的臨床服務營收機會佛羅里達州坦帕市, 2026年5月13日 - (亞太商訊 via SeaPRwire.com) - 領先的醫療科技與藥品分銷公司 Wellgistics Health, Inc.（納斯達克代碼：WGRX）（以下簡稱「Wellgistics」或「本公司」）今日宣布，將與 Kare PharmTech 及 Kare Clinicals 展開試點合作，整合其醫療服務組織（MSO）基礎設施，以支援參與計畫的醫療機構所提供的慢性病照護管理（CCM）及遠端病患監測（RPM）服務。根據第三方產業報告，隨著醫療服務提供者持續轉向價值導向及居家照護模式，美國 RPM 市場目前規模為 140 億美元，預計到 2030 年將達到約 290 億美元，年複合成長率（CAGR）為 12.6%。¹該試點計畫目前涵蓋多家醫療機構，由 Kare Clinicals MSO 代表參與的醫療機構及提供服務的醫療人員擔任帳務處理機構。此計畫旨在透過可擴展的營運流程及科技驅動的工作流程，支援患者參與、照護協調及縱向監測計畫。所有慢性病管理（CCM）及遠距患者監測（RPM）服務，均預期將由持有適當執照的醫療人員及參與實體，依照適用的聯邦與州醫療保健法律、給付要求及支付方計畫規則提供並進行帳務處理。相關企業表示，試點基礎設施已產生超過 1,500 筆理賠申請，並將作為未來擴展計畫的基礎，目標是逐步涵蓋更多醫療服務提供者。作為合作計畫的一部分，Wellgistics Health 擬運用其超過 6,500 家獨立藥局的網絡，協助識別並支援可能從 CCM 和 RPM 服務中受益的合資格患者。隸屬於 Wellgistics 藥局網絡的參與藥局，亦可能有機會參與與該計畫相關的臨床互動計畫。Wellgistics Health, Inc. 總裁兼執行長 Prashant Patel 表示：「我們相信，藥局互動、醫療提供者連結以及科技驅動的照護協調三者的融合，不僅能顯著改善患者治療成效，同時也能為獨立藥局創造新的經濟機會。透過此次與 Kare PharmTech 的試點合作，我們正建立一套基礎架構，旨在支援慢性病管理及遠程患者監測計畫中可擴展的患者參與模式。」Kare PharmTech 創辦人兼執行長米塔爾·帕內拉（Mital Panera）補充道：「我們一直致力於打造一個營運高效的醫療服務組織（MSO）平台，能夠協助醫療提供者進行照護協調與給付流程管理。透過與 Wellgistics Health 及其藥局網絡合作，我們相信能進一步擴大患者參與度、提升照護連續性，並為未來醫療服務提供者的成長建立可擴展的框架。」雙方指出，隨著擴展計畫持續推進，此試點計畫仍須視營運發展、醫療服務提供者參與度及法規遵循等因素而定。關於 Wellgistics Health, Inc.Wellgistics Health（納斯達克代碼：WGRX）是健康資訊科技領域的領導者，將其專有的藥房調劑優化人工智慧平台 EinsteinRx™ 整合至其獲得專利的區塊鏈智慧合約平台 PharmacyChain™ 中，以優化處方藥調劑流程。其整合平台串聯了 6,500 多家藥局（「Wellgistics 藥局網絡」）及 200 多家製造商，提供批發分銷、數位處方箋傳輸、直接送達患者，以及由人工智慧驅動的樞紐服務，例如資格審核、用藥遵從性管理、新用戶註冊、事前授權，以及依需求提供的自費處方箋履約服務，以優化患者的用藥可及性。Wellgistics 提供端到端的解決方案，旨在為美國獨立藥房恢復處方藥市場的獲取管道、透明度及信任。關於 Kare PharmTech, LLC關於 Kare PharmTech, LLCKare Clinicals 隸屬於 Kare PharmTech, LLC 旗下更廣泛的企業生態系統，該公司由 Kiran Patel 博士掌控。Patel 博士於 1992 年創立了 Medicaid 服務供應商 WellCare，並於 2002 年以 2 億美元的價格將其出售。2007年，帕特爾博士創立了 America's 1st Choice Holdings，並收購了 Freedom Health 和 Optimum Holdings。2017年，他將 America's 1st Choice Holdings 出售給 Anthem, Inc.。帕特爾博士是一位知名慈善家，曾獲《佛羅里達趨勢》雜誌評選為「年度佛羅里達人」。前瞻性陳述本新聞稿包含《1995年私人證券訴訟改革法案》所定義的前瞻性陳述。前瞻性陳述包括有關本公司預期、信念、計劃、目標、意圖、策略、未來事件或表現的陳述，包括關於與 Kare PharmTech 及 Kare Clinicals 進行的試點合作所帶來的潛在效益、可擴展性、擴展、商業化、供應商參與、報銷機會、患者參與計劃、營運能力及未來發展，以及 Wellgistics 藥房網絡在支援 CCM 和 RPM 計劃方面預期所扮演的角色。諸如「預期」、「相信」、「可能」、「期望」、「意圖」、「或許」、「計劃」、「潛在」、「預測」、「尋求」、「應」、「將」等詞彙及類似表述，旨在識別前瞻性陳述。這些前瞻性陳述基於當前的預期與假設，並涉及可能導致實際結果與該等陳述所表達或暗示者存在重大差異的風險與不確定性。此類風險與不確定性包括但不限於：與醫療服務提供者採用與參與相關的風險、報銷結果、患者參與程度、營運執行、試點計畫的可擴展性、監管與醫療保健合規考量、適用法律或報銷政策變更、市場對本公司服務的接受度、競爭因素，以及本公司建立並維持戰略關係及成功實施其商業策略的能力。本新聞稿所述之試點合作屬探索性質，無法保證該計畫將帶來擴大的商業關係、重大營收機會或長期營運成功。有關上述及其他風險的更多資訊，可參閱本公司向美國證券交易委員會提交的文件，包括其中所載的風險因素。除法律規定外，本公司無義務因新資訊、未來事件或其他原因而更新或修訂任何前瞻性陳述。Wellgistics 媒體與投資者聯絡資訊媒體：media@wellgisticshealth.com投資者關係：IR@wellgisticshealth.com[1] MarketsandMarkets - 美國遠程患者監測市場報告來源：Wellgistics Health, Inc. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Recently, in its latest Tear Sheet, S&P Global stated that it expects Guotai Junan International Holdings Limited (“Guotai Junan International” or “GTJAI”, Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, and its intermediate holding company Guotai Haitong Financial Holdings Ltd. (“GTHTFH”), to continue to play a key role in the international strategy of their ultimate parent Guotai Haitong Securities Co. Ltd. (“GTHT”).In its Tear Sheet, S&P Global pointed out that the business synergies between GTJAI and its parent company, particularly in investment banking and wealth management, reinforce its importance within the group. International development is one of GTHT’s core strategic priorities, and GTJAI will continue to play a key role in the Group’s efforts to strengthen its global presence. In 2025, GTJAI and GTHTFH recorded 284% and 85% profits growth, respectively, and accounted for about 3% and 8% of GTHT’s net profit during the year. This strong financial performance robustly demonstrates the Company’s contribution to the overall business of the Group.S&P Global expects that GTJAI will remain one of the Group’s core subsidiaries over the next two years and will continue to receive support from GTHT, with its issuer credit rating and “stable” outlook moving in tandem with those of the parent. S&P Global believes that GTJAI has access to timely parental support, including indirect benefits from the Shanghai government through GTHT if needed.This Tear Sheet fully reflects the Company’s current situation and expectations for future development. GTJAI will resolutely align with the Group’s international strategy, continuously enhance its own professional capabilities and the efficiency of business synergies with the Group, and contribute to Guotai Haitong Group’s goal of becoming a first-class investment bank with international competitiveness and market leadership.Note: This article is based on an independent opinion document (Tear Sheet: Guotai Junan International Holdings Ltd. And Guotai Haitong Financial Holdings Ltd.) published by S&P Global Ratings on May 5, 2026. This document does not constitute a rating action.About GTJAIGuotai Junan International (Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes wealth management, institutional investor services, corporate finance services, investment management and other business. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “AAA” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 81% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH/ 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年5月13日 - (亞太商訊 via SeaPRwire.com) - 近日，標普全球（S&P Global）在其發佈的最新簡報中明確表示，預計國泰海通集團下屬公司國泰君安國際控股有限公司（「國泰君安國際」、「公司」，股份代號：1788.HK）及其直接控股公司國泰海通金融控股有限公司（「國泰海通金控」）作為母公司國泰海通證券股份有限公司（「國泰海通」）核心子公司，將繼續在集團國際化戰略中發揮關鍵作用。標普全球在簡報中指出，國泰君安國際與母公司在投資銀行及財富管理領域的業務協同效應顯著，進一步強化了其在集團內部的重要性。國際化發展為國泰海通的核心戰略重點之一，國泰君安國際將繼續在集團加強全球佈局的過程中扮演關鍵角色。2025年，國泰君安國際及國泰海通金控分別實現利潤增長284%及85%，分別占國泰海通證券當年淨利潤約3%及8%。這一強勁的財務表現，有力印證了公司對集團整體業務發展的貢獻。標普全球預期，國泰君安國際未來兩年仍將作為集團核心子公司之一，持續獲得母公司支持，其發行人信用評級及「穩定」展望將與母公司保持同步。標普全球認為，公司可獲得母公司穩定、及時的支持，包括在必要時通過國泰海通間接受益於上海政府的資源。這份簡報充分反應了公司的現況及對未來發展的預期。國泰君安國際將堅定不移地配合集團國際化戰略，持續提升自身的專業能力及與集團的業務協同效率，為國泰海通集團成為具備國際競爭力與市場引領力的一流投資銀行作出貢獻。注：本文內容基於標普全球評級於2026年5月5日發佈的獨立觀點檔（Tear Sheet：Guotai Junan International Holdings Ltd. And Guotai Haitong Financial Holdings Ltd.），該文件不構成評級行動。關於國泰君安國際國泰海通集團下屬公司國泰君安國際（股票代號：1788.HK），是中國證券公司國際化的先行者和引領者，公司是首家通過IPO於香港聯合交易所主機板上市的中資證券公司。國泰君安國際以香港爲業務基地，幷在新加坡、越南和澳門設立子公司，業務覆蓋全球主要市場，爲客戶境外資産配置提供高質量、多元化的綜合性金融服務，核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前，國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級，MSCI ESG「AAA」評級, Wind ESG「A」評級及商道融綠ESG「A」評級，同時其標普全球ESG評分領先全球81%同業。公司控股股東國泰海通證券（股票代號：601211.SH/2611.HK）爲中國資本市場長期、持續、全面領先的綜合金融服務商。更多關于國泰君安國際的資訊請見:https://www.gtjai.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - The sixth Asia Summit on Global Health (ASGH), jointly organised by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Development Council (HKTDC), and the 17th Hong Kong International Medical and Healthcare Fair (Medical Fair), organised by the HKTDC and co-organised by the Hong Kong MedTech Association, have concluded successfully. As one of the two flagship events of International Healthcare Week, the ASGH gathered some 3,000 participants from 43 countries and regions and arranged over 400 one‑on‑one deal-making meetings, while also facilitating the signing of multiple cooperation agreements, with a strong focus on the application of artificial intelligence. Meanwhile, the Medical Fair welcomed some 13,000 buyers from 61 countries and regions for sourcing and networking. More than 670 business matching meetings were arranged during the fair, supporting buyers and exhibitors in identifying potential partners and advancing concrete business discussions. Together, the two flagship events facilitated over 1,000 high-quality collaborations and connections, fully demonstrating the synergy between medical technology, investment and industry applications.Over 90 global leaders share insight into healthcare innovation development and AI applicationsThe sixth ASGH, a two-day event jointly organised by the Government of the Hong Kong Special Administrative Region and the HKTDC, has concluded under the theme Fuelling Healthcare Breakthroughs, focusing on public health, frontier healthcare technologies, AI breakthroughs, healthcare investment and the silver health. The ASGH brought together over 90 international healthcare officials, scientific pioneers, Nobel laureate, investors and corporate leaders to share insight and explore pathways to accelerate innovation across the global healthcare ecosystem.At Plenary Session I – Strengthening Pandemic Preparedness through Global Collaboration. Prof Ibrahim Abubakar, Vice‑Provost (Health) and Professor of Infectious Disease Epidemiology, University College London, said: “Research platforms need to be developed long in advance of pandemics, and we must invest in infectious disease infrastructure, and beyond, whether it’s in AI technology or in disease management.”Plenary Session II – Fuelling Healthcare Breakthroughs centred on the commercialisation of medical research, biomedical innovation and healthcare investment opportunities. Jonathan Symonds, Chair of GSK, said: “All developed countries are now facing ageing, low birth rates and an increasing impact of chronic disease. So, it's no longer just a health system problem, but it's now an economic problem.”During the Dialogue with Global Pioneer in Health session, Prof Michael Levitt, 2013 Nobel Laureate in Chemistry and Robert W and Vivian K Cahill Professor of Cancer Research at the Stanford University School of Medicine, said that Hong Kong’s healthcare system possesses unique advantages and high-quality statistical data, making it potentially more valuable for research than the US and other countries or regions, in areas such as longevity.The ASGH featured multiple thematic sessions spotlighting the application of AI in healthcare. Sustaining the momentum of the “Intelligence at Scale: How AI is Powering Real-World Healthcare Revolution” session on the first day, another thematic session on the second day, “Transforming Healthcare through Digital Health & AI Innovations”, explored how digital technologies and artificial intelligence are reshaping healthcare systems. Natasha Chhatrapati, Senior Director, Business Transformation Lead for International, Pfizer Inc., said: “AI is compressing timelines across the entire healthcare journey, from drug development and clinical research to how we engage with physicians and how patients consume care.”The session “The Next Frontier in China’s Healthcare Industry” examined strategies to advance the Chinese Mainland healthcare sector. Dr James Xue, Founder, Chairman and CEO of CANbridge Pharmaceuticals Inc, said: “China has an edge because of the population. A bigger population base will allow companies to build better drug candidates.”With silver health emerging as a major global focus, the Silver Health Chapter included the session “Unlocking Growth in Silver Health: From Precision Medicine to Smart Ageing Innovations”, which brought together leading experts to discuss challenges and opportunities arising from population ageing. Dr Alex Mihailidis, Associate Vice‑President, International Partnerships and Professor at the University of Toronto and Scientific Director at AGE‑WELL, provided in‑depth insight into breakthroughs in prevention and treatment of age‑related diseases, offering guidance for the development of the silver health economy and smart ageing solutions. He said: “For a technology to be successful with older people, it’s not just the technology, but also the service delivery model, as well as the practice and policy.”The newly introduced session “CSO Insights: Catalysing Scientific Breakthroughs and Investments for Future Health” featured discussions on research strategy and the acceleration of scientific discoveries into practical applications. Dr Li Xiang, Senior Vice President, Co-President and Chief Scientific Officer, Innovative Medicines Division, Fosun Pharma, said: “In our business, it is very important to begin with the end in mind. When you set out to do your discovery program, you must already know what the unmet needs are and how difficult the clinical trials will be.”Over 400 deal‑making sessions drive investment and business matchingBeyond thought leadership, the ASGH continued to serve as an effective platform for deal‑making and investment matching. Dedicated deal-making at the ASGH facilitated one‑to‑one meetings to promote tangible collaboration.During the ASGH, over 400 business and investment matching meetings were arranged, attracting investment institutions and healthcare enterprises from Europe, the US, Asia and the Guangdong‑Hong Kong‑Macao Greater Bay Area to explore opportunities in investment, technology deployment and market expansion.Colin Tan, Director of Operations at TusPark Holdings, an investor from the UK, said: “This year, I brought around 15 UK healthcare and life sciences companies to exhibit at the UK Pavilion. The ASGH has been an excellent platform to forge such connections. We are now facilitating a significant partnership in cancer research between a leading UK organisation and a Hong Kong counterpart.”ASGH also featured the ASGH Business Hub and the InnoHealth Showcase, bringing together some 180 healthcare innovation companies from 12 countries and regions to present cutting‑edge solutions across biotechnology, digital health and medical technologies.Strategic Partner of this year’s Summit, Shanghai Industrial Investment (Holdings) led multiple subsidiaries in exhibiting at the ASGH. Gu Feng, Chief Finance and Investment Officer, said that the ASGH fully showcased Hong Kong’s international competitiveness: “Chinese companies expanding overseas will come to Hong Kong, and foreign companies seeking to procure will do the same. Here we can not only acquire resources, but also connect and match resources, talent, capital, and other key elements.”AQ Biotech from Finland, exhibiting at ASGH for the first time, said that their objective was to explore the Asian market. They view Hong Kong as a vital hub that adds internationally recognised credibility, connectivity and commercial acumen, helping them take their work global.Dr Iman Manavitehrani, Founder and Director of SDIP Innovations, the Australian exhibitor returning for the second year, said: “Last year’s visit led directly to an IGNITE grant from HSITP, and we are now part of the first Australian cohort based here. With Hong Kong as our gateway to the GBA and Chinese Mainland, I am confident the connections made at the ASGH will lead to further collaboration and partnership.”Third-time exhibitor, Prof Leung Kam-tong, Founder and CEO of local healthcare startup Homing Pharmaceuticals, said: “We’ve already reconnected with three investors here for in-depth discussions on our fundraising strategy, taking our navigated CAR-T therapy to first-in-human clinical trials. Sessions outside my field sparked new ideas around refining the therapy and exploring new directions. I also met professors from Australia and Singapore, and look forward to exploring international R&D collaborations as we bring this therapy worldwide.”Building bridges for “go global” and other cross‑border healthcare collaborationsBuilding on its track record of facilitating collaboration, the ASGH enabled the signing of 10 Memoranda of Understanding (MoUs), such as those between the HKSH Medical Group and Siemens Healthineers, as well as Australian AI-powered clinical documentation platform startup Heidi Health, which signed separate agreements with local medical group EC Healthcare and Hong Kong Metropolitan University. These collaborations will drive deeper cooperation, including AI‑enabled healthcare applications and clinical research, further reinforced the ASGH’s role as a bridge connecting the Chinese Mainland and international healthcare ecosystems. Notably, HKSH Medical Group and Siemens Healthineers signed an agreement, formally establishing HKSH as Siemens Healthineers’ first Photon Counting Computed Tomography Simulation (PCCT-Sim) Reference Site in Asia.On the second day, the GoGlobal CONNECT series: Hong Kong as a Superconnector to Empower Global Expansion of Pharmaceutical Enterprises workshop brought together experts in regulation, clinical trials, IP protection and distribution to share practical insight on international expansion. Prof Bernard Cheung, Chief Executive Officer, Greater Bay Area International Clinical Trial Institute, said: “Public hospitals in Hong Kong have very good electronic medical records that go back 30 years. It’s a unique asset that benefits not just people in Hong Kong but the world, as it allows us to study the long-term progression of diseases.”The ASGH also featured the “GoGlobal Connect” and the Business of Healthcare Advisory Zone, enabling healthcare enterprises to connect with service providers and receive practical support for developing “go global” strategies. Xiang Jun, Chairman of 365 Intelligence (Beijing) Medical Technology Co., Ltd, said that the ASGH helped them gain a deeper understanding of Hong Kong’s professional services and of HKTDC’s “GoGlobal Connect” initiative. The company is particularly interested in Hong Kong’s research data and service resources, and plans to establish research operations in Hong Kong in the long term. Mark Xu, Regional Director of Sales and Marketing, Guangzhou Wondfo Biotech Co, Ltd, also successfully connected with service providers, including DKSH and the Greater Bay Area International Clinical Trial Institute, through this workshop. They engaged in in-depth discussions on potential collaboration opportunities for “going global”.During the summit, the HKTDC signed a Memorandum of Understanding with the Hong Kong Singapore Business Association (HSBA), supporting Mainland enterprises’ “going global” via Hong Kong to target the Singapore and ASEAN markets. Prime Minister and Minister for Finance of Singapore Lawrence Wong visited Hong Kong in March this year, during which both governments agreed to deepen cooperation. The HSBA and the HKTDC, together with professional service providers, plan to strengthen trade and economic ties between the two cities. By leveraging their respective strengths and promoting complementary cooperation, they aim to drive business development, assist Chinese Mainland enterprises in expanding regionally and internationally, and enhance tripartite collaboration among Singapore, Hong Kong, and the Chinese Mainland.The Medical Fair brings together global industry players to foster diverse collaborations, strengthening Hong Kong’s status as a global healthcare hubThe Medical Fair was being held concurrently. Organised by the HKTDC and co-organised by the Hong Kong MedTech Association, the Medical Fair adopted the theme Innovations Boosting Smart Health Experience. Focusing on three key areas: MedTech, GeronTech, and Preventive Healthcare, the event provided a high-efficiency trade and matchmaking platform for global R&D institutions, manufacturers, and medical professionals to showcase the latest industry trends. The number of exhibitors featuring smart ageing products and green solutions doubled this year, with many showcasing innovative solutions integrating AI and robotics to meet evolving market demands.The Medical Fair featured some 300 exhibitors from 10 countries and regions, including Hong Kong, Chinese Mainland, Macao, Taiwan, Australia, Canada, Korea, New Zealand, United States and Vietnam. The Fair featured seven major zones, including Startup Zone, Hospital Equipment and Digital Health, Biotech and Lab Diagnostics, Laboratory Technologies and Healthcare Services, Medical Supplies, and the World of Health and Wellness, showcasing the latest medical technologies and innovative solutions. Pavilions from leading local universities, the Hong Kong Science and Technology Parks, and the Hong Kong MedTech Association underscored a multi-sector commitment to fostering collaborative innovation across government, industry, academia, research, and investment sectors.Exhibitors acknowledged that AI has become a core driver of healthcare services, while the Medical Fair serves as a one-stop platform that brings together a complete healthcare ecosystem, successfully integrating AI, robotics technology and a wide range of smart medical devices. Wong Cheung Hang, Sales and Marketing Manager of Health Care & Co, a medical and rehabilitation equipment company in Hong Kong, said, “Buyers showed particular interest in our AI management systems, AI-assisted robots and various smart healthcare applications. With healthcare providers increasingly adopting smart health solutions, the market outlook is promising. We expect this fair to drive at least 20% business growth compared with last edition and enable us to promote smart rehabilitation technologies.” Many overseas exhibitors succeeded in securing business matching opportunities at the fair. Peter Li, Chief Executive Officer of first-time exhibitor GenomeMe Lab Inc from Canada, said, “We connected with buyers from Hong Kong, Thailand and India, and identified potential local partners in the healthcare and hospital sectors. This will help us explore entry into hospital channels, establish distribution networks, and lay the groundwork for future expansion into Southeast Asia, Australia and Korea.”The Medical Fair has facilitated numerous cross-regional collaborations, serving as a key platform for industry exchange and business matching. Dresio Limited, participating in the Fair for the third time under the banner of Hong Kong Science and Technology Parks, showcased its contactless physiotherapy assessment system Accudex, drawing strong interest from buyers across Hong Kong, Chinese Mainland, Singapore and the Philippines. Curtis Wong, Chief Operating Officer and Head of Research and Development of the company, said, “This year’s fair outperformed previous editions in footfall, business exchanges and partnership discussions. We have engaged with a large number of high-quality buyers from hospitals, rehabilitation centres and the insurance sector.” The company met with a Filipino buyer on the first day of the exhibition and subsequently signed a Memorandum of Understanding (MOU) on the third day, expanding its software into Southeast Asia, with the contract value expected to exceed HK$1 million.The Medical Fair was held concurrently with the ASGH and the Hospital Authority (HA) Convention, bringing together key industry stakeholders and generating strong synergy. Exhibitors were able to seize the opportunity to meet with numerous representatives from the Hospital Authority and major healthcare institutions, fostering meaningful exchanges and collaboration. Among them, first-time exhibitor PalmX Technology Limited showcased its palm vein biometric technology at the Startup Zone. Jeffrey Lo, Vice President of the company, was impressed by the Fair’s response, which exceeded his expectations. He added that within the first two days, they received over 20 enquiries from hospitals and healthcare institutions, including representatives from the Hospital Authority, and attracted interest from overseas buyers in Thailand, Indonesia, the Philippines and India, with potential orders ranging from US$10,000 to several hundred thousand dollars.This year’s Medical Fair attracted a significant number of buyers from emerging markets seeking sourcing opportunities. Dr Keo Sovann, an otorhinolaryngologist from Orchid Hospital in Cambodia who visited the fair specifically for new medical equipment, said, “I met more than 10 exhibitors from Chinese Mainland, Australia and Malaysia, which has helped expanding our hospital’s procurement network and advanced our internationalization efforts. I am particularly interested in a Hong Kong company’s AI-powered medical imaging solutions and X-ray equipment; we are considering an order of 20 units.” A buyer from Morocco also attended the fair for the first time to source laboratory equipment. Rachid Zemmouri, Business Development Manager of Promamec, said he met with at least 15 exhibitors from Hong Kong, Chinese Mainland, Taiwan and Indonesia. Discussions are underway on thermodynamics-related solutions with the aim of application to eye-disease treatment. Subject to satisfactory progress, he plans to invite partners to Morocco for site visits. He added that the company has an annual procurement budget of approximately US$70 million and intends to return for future sourcing.The Fair hosted over 50 themed forums and seminars, with leading technology companies, industry experts and academics sharing the latest industry trends, technological innovations and practical insights to foster in-depth exchange, collaboration and inspire trade buyers. Highlight sessions included “Accelerating Mental Health Innovation through AI Research and Adoption”, “HKMTA Medical Fair Forum 2026: The Medtech Solutions - Greater Bay Area & Overseas”, “The ASEAN Gateway: Navigating Regulations, Capital and Distributions from Hong Kong”, and “Decoding the Demand for Gerontechnology” among others, all of which attracted strong audience engagement. Selected sessions are available for replay on the Fair’s website for extended engagement.The exhibition continued to adopt the EXHIBITION+ hybrid model. Global exhibitors, industry professionals, and buyers could make use of the Click2Match and explore sourcing opportunities via HKTDC Sourcing. Click2Match will remain available until 20 May.Photo download: https://bit.ly/4nokRfTThe sixth Asia Summit on Global Health was attended by some 3,000 participants from 43 countries and regions.Dr Alex Mihailidis, Associate Vice President, International Partnerships and Professor at the University of Toronto and Scientific Director at AGE WELL, attended and shared his insight.In the session Transforming Healthcare through Digital Health & AI Innovations, Natasha Chhatrapati, Senior Director, Business Transformation Lead for International at Pfizer Inc, engaged with fellow panellists to examine the practical implementation and the latest breakthroughs in AI within the healthcare sector.On the second day, the GoGlobal CONNECT series: Hong Kong as a Superconnector to Empower Global Expansion of Pharmaceutical Enterprises brought together experts in regulation, clinical trials, IP protection and distribution to share practical insights on international expansion.During the ASGH, over 400 business and investment matching meetings were arranged, attracting investment institutions and healthcare enterprises from Europe, Asia and the Guangdong‑Hong Kong‑Macao Greater Bay Area to explore opportunities in investment, technology deployment and market expansion.The ASGH also featured the ASGH Business Hub and the InnoHealth Showcase, bringing together around 180 healthcare innovation companies from 12 countries and regions to present cutting‑edge solutions across biotechnology, digital health and medical technologies.The ASGH also featured the “GoGlobal Connect” and the Business of Healthcare Advisory Zone, enabling healthcare enterprises to connect with service providers and receive practical support for developing “go global” strategies.HKTDC signed a Memorandum of Understanding with the Hong Kong Singapore Business Association (HSBA), supporting Mainland enterprises to “go global” via Hong Kong and target the Singapore and ASEAN markets.The 17th Hong Kong International Medical and Healthcare Fair attracted buyers from 61 countries and regions, with some 13,000 buyers visiting the fair for sourcing and procurement.The Hong Kong MedTech Association led some 20 companies to exhibit at the fair, drawing strong buyer interest and encouraging in‑depth business discussions.The Canada Pavilion brought together a number of companies to promote their medical equipment, technology application solutions and related services, attracting buyers to explore opportunities and engage in business discussions.Hong Kong Science and Technology Parks Corporation led over 30 innovation and technology companies to exhibit at the Fair, showcasing the strength of Hong Kong’s local medical innovation and R&D capabilities.Industry experts at the themed session “ASEAN Gateway: Navigating Regulations, Capital and Distributions from Hong Kong” shared the latest market trends, fostering active exchanges among industry stakeholders.WebsitesInternational Healthcare Week: https://internationalhealthcareweek.hktdc.com/enAsia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/enHong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/enList of Product: https://www.hktdc.com/event/hkmedicalfair/en/product Media enquiriesYuan Tung Financial Relations:Jasmine ZhangTel: (852) 3428 3278Email: jzhang@yuantung.com.hkLouise SongTel: (852) 3428 5691Email: lsong@yuantung.com.hkTiffany LeungTel: (852) 3428 2361Email: tleung@yuantung.com.hkHKTDC’s Communications & Public Affairs Department:Noah QiuTel: (852) 2584 4575Email: noah.yl.qiu@hktdc.orgNavin LawTel: (852) 2584 4525Email: navin.cm.law@hktdc.orgSerena CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

美國佛羅里達州奧蘭多，2026年5月13日 - (亞太商訊 via SeaPRwire.com) - 在 2026 SAP Sapphire 大會上，SAP SE（紐交所代號：SAP）正式發布「自主營運企業（Autonomous Enterprise）」願景，旨在優化全球最核心的業務流程，讓人與 AI 無縫協作，在安全可控的前提下，以更高效率、更具策略性的方式，應對日益增長的全球商業需求。SAP 全球CEO柯睿安（Christian Klein）表示：「對於客戶的關鍵任務流程而言，『差不多對』是遠遠不夠的。透過將 SAP Business AI 平台與 SAP自主型管理套件(Autonomous Suite) 結合，我們把 AI agents 深度嵌入業務流程、數據及治理框架之中，確保其能夠提供準確、合乎規格且安全的結果，從而開拓全新增長機遇，並帶來實質的成本節省與效率提升。」Autonomous Enterprise包含一個統一的 AI 平台，用於構建及治理 AI agents，並為其提供業務脈絡；同時亦包括一個可執行核心業務流程的自主型管理套件，以及重新定義人與企業軟件互動方式的全新用戶體驗。推出 SAP Business AI平台SAP Business AI作為全新的基礎平台，專為構建及部署基於真實業務場景的企業級 AI 而設。SAP Business AI 平台將 SAP Business Technology Platform、SAP Business Data Cloud 及 SAP Business AI 整合於一個統一、受監管的環境中。SAP Business AI 平台的核心為 SAP Knowledge Graph，它就像為 AI agents 提供一張結構化的業務地圖，清晰呈現客戶 SAP 系統環境中的每個業務實體、流程及關聯。Joule Studio 是 SAP 面向企業 AI agents、應用程式及 AI agent 工作流構建的 AI 優先解決方案。開發人員可利用 SAP 提供的安全、可擴展，並專為企業級 AI 優化的託管基礎設施，使用自己偏好的無程式碼、專業程式碼及 AI 開發框架進行開發。跨業務職能及行業中部署SAP Autonomous Suite在此基礎上，SAP 亦進一步推出 SAP Autonomous Suite。讓現有業務應用具備 AI agents 能力，從而端到端自主執行業務流程。該套件於財務、供應鏈、採購、人力資本管理及客戶體驗等範疇，部署超過 50 個按業務領域專屬（Domain-specific）的 Joule Assistants。這些assistants透過協調逾 200 個專門 AI agents，實現端到端流程全自動化。例如，全新的Autonomous Close Assistant可透過自動處理日記賬、對賬及錯誤修正，將財務結賬流程由數星期縮短至數天。此外，SAP 發布了 Industry AI，透過七大行業自主型解決方案，進一步擴展其深厚的行業能力。這些方案不僅可端到端執行完整的行業流程，更內置特定行業專屬業務邏輯、數據模型及規格與監管要求。在本次大會上，SAP 展示了與歐洲能源巨頭RWE的合作成果，利用Industry AI幫助減少其海上風力渦輪機的意外停機時間。借助 SAP 的 Autonomous Asset Management 場景，AI agents 可分析數千宗歷史事故數據，識別最可能的根本原因，並自動生成已預填的工作單，附上合適工具建議及有效的修復方案。設計自主型用戶體驗Joule Work也是今次大會的重點發布之一，重新定義了用戶與 SAP 軟件的互動方式。用戶現在不再需要在各個應用之間切換，或於多個畫面手動輸入資料，而是可以直接與 Joule 互動。只要描述所需的業務成果，Joule 便會協調合適的工作流程、數據及 AI agents 完成任務。Joule Work 不單止是對話工具，更會主動呈現相關業務洞察，並在背景自動處理日常任務，令工作即使在人类未主動操控時亦能持續推進。該方案將支援桌面、流動裝置及語音操作，並可跨 SAP 及非 SAP 系統使用。投資1億歐元 加快客戶邁向自主營運SAP 全面升級了客戶及合作夥伴計劃，加快各類企業轉型邁向 Autonomous Enterprise。為促進落實及採用，SAP設立了一項1億歐元的專屬基金，用於支援合作夥伴協助客戶部署由 SAP 開發的 AI assistants 及 AI agents。該基金亦用於支持合作夥伴基於Joule Studio，在 SAP Business AI 平台上延伸或開發全新合作夥伴 AI agents。SAP 同時升級 RISE with SAP 與 SAP GROW 的方案權益，以促進客戶採用 AI。兩者均可使用 Joule Assistants產品組合；RISE with SAP客戶可於首年內啟用 3 個 Joule assistants，而 SAP GROW 客戶則可於上線後即獲得完整 Joule assistants方案的使用權。至於 SAP S/4HANA 本地部署客戶及 SAP ERP Central Component（SAP ECC）客戶，SAP 亦提供相應支援：客戶只要承諾將現有大部分系統遷移至 SAP Cloud ERP，即可獲得部分 AI 場景的使用權，從而在現有系統環境與雲端目標架構之間實現無縫過渡。此外，SAP 亦推出 agent-led transformation 的轉型工具，可將 ERP 系統遷移工作量減少 35%以上，透過大規模自動化系統分析、代碼修復、配置及測試，加快項目推進，並提升可預測性。此外，SAP 亦宣布全方位拓展策略合作夥伴關係︰- 在平台與套件層面： - SAP將與Anthropic合作，將Claude基礎模型引入SAP的AI平台，用於支援涵蓋人力資源、採購及供應鏈等場景的 Joule Agentic AI； - 與Amazon Web Services合作，實現SAP Business Data Cloud與Amazon Athena之間的零複製數據整合； - 與Google Cloud及Microsoft合作，實現Joule 與外部Agentic AI框架之間的雙向agent-to-agent互操作； - 與Mistral AI及Cohere合作，在SAP云基礎設施上提供主權模型選項； - 與n8n合作，在Joule Studio內提供可視化AI工作流程編排能力； - 與NVIDIA合作，借助其OpenShell為Joule Studio提供安全可靠的運行環境； - 與Parloa合作，將AI agents引入SAP Service Cloud，使其可在全面存取業務數據與服務流程的基礎上，處理客戶互動。- 在實施層面︰ - SAP將與Palantir及Accenture圍繞複雜數據遷移場景展開合作，並與Conduct合作，推動AI驅動的SAP EPR Cloud遷移。更多內容請參閱《SAP Sappire 2026 創新新聞指南》圖片下載：https://bit.ly/42zNb5h關於SAP作為企業應用和商業AI的全球領導者，SAP位於商業和技術的交匯點。50多年來，企業一直信賴SAP通過整合財務、採購、人力資源、供應鏈和客戶體驗等核心業務營運，來發揮其最佳表現。如需瞭解更多SAP資訊，請瀏覽https://www.sap.com/hk 。如要查詢更多資訊，請聯絡（只限傳媒）：縱橫傳訊顧問有限公司（SCC）Andico Tsuiandico.tsui@sprg.com.hk+852 2114 4346 / 6902 3831 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ORLANDO, FL, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - At SAP Sapphire in 2026, SAP SE (NYSE: SAP) introduced the Autonomous Enterprise to help enhance the world’s most critical business workflows, so that humans and AI work together to meet the accelerating demands of global business profitably, strategically and safely. “For the mission-critical processes of our customers, ‘almost right’ just isn’t good enough,” said Christian Klein, CEO of SAP SE. “By uniting SAP Business AI Platform with SAP Autonomous Suite, we anchor AI agents in the business processes, data and governance so they can deliver accurate, compliant and secure outcomes, unlocking new sources of revenue and meaningful cost savings.”The Autonomous Enterprise includes a unified AI platform for building, contextualizing and governing agents, an autonomous suite that executes core business operations and a new user experience that redefines how people work with enterprise software.Introducing SAP Business AI PlatformSAP Business AI Platform is a new foundation for building and deploying enterprise AI grounded in real business context. SAP Business AI Platform now unifies SAP Business Technology Platform, SAP Business Data Cloud and SAP Business AI into a single, governed environment.At its core is the SAP Knowledge Graph solution, which gives AI agents a structured map of business entities, processes and relationships across a customer’s SAP landscape. Joule Studio is SAP’s AI-first solution for building enterprise agents, applications and agentic workflows. Developers can build using the no-code, pro-code and AI frameworks of their choice on SAP-managed infrastructure that is secure, scalable and optimized for enterprise AI.Deploying SAP Autonomous Suite Across Every Business Function and IndustryBuilding on this foundation, SAP also introduced SAP Autonomous Suite, which enables SAP’s existing business applications with AI agents capable of running processes from start-to-finish.The suite will deploy more than 50 domain-specific Joule Assistants across finance, supply chain, procurement, human capital management and customer experience. These assistants will automate end-to-end processes by orchestrating a subset of over 200 specialized agents to execute precise tasks. For example, the new Autonomous Close Assistant can compress the financial close process from weeks to days by automating journal entries, reconciliation and error resolution across the entire process.SAP also launched Industry AI, expanding its deep industry portfolio through seven autonomous solutions that will enable start-to-finish industry processes and embed sector-specific process logic, data models and regulatory requirements. At SAP Sapphire, SAP showcased its work with European energy giant RWE to leverage Industry AI, helping reduce unplanned downtime across its offshore wind turbines. With SAP’s Autonomous Asset Management scenario, AI agents are designed to analyze data from thousands of past incidents, identify the likely root cause and generate pre-filled work orders with the right tools and proven fixes from other sites.Designing the Autonomous User ExperienceThe company also revealed Joule Work, redefining how users engage with SAP software. Instead of navigating individual applications and entering data across several screens, users will now interact primarily with Joule. By describing a desired business outcome, Joule will orchestrate the right combination of workflows, data and agents to get it done.Joule Work goes beyond conversation, proactively surfacing relevant insights and automating routine tasks behind the scenes so work moves forward even when humans aren’t actively steering it. It will be available on desktop, mobile and voice across SAP and non-SAP systems.Accelerating the Customer Journey Toward Autonomy with €100 Million InfusionSAP evolved its customer and partner programs to help accelerate the organization’s journey to the Autonomous Enterprise. To catalyze adoption, the company has launched a €100 million fund for SAP partners to help customers deploy SAP-built AI assistants and agents. The fund is also available to partners that extend or build new partner agents on the new SAP Business AI Platform using Joule Studio.SAP has enhanced its RISE with SAP and SAP GROW offerings to accelerate AI adoption. Both include access to the Joule Assistants portfolio; RISE with SAP customers will have three assistants activated within their first year, while SAP GROW customers receive full portfolio access at onboarding. SAP S/4HANA on-premises and SAP ERP Central Component (SAP ECC) customers are not excluded: those that commit to transitioning the majority of their current landscape to SAP Cloud ERP gain access to select AI scenarios, bridging the gap between their current landscape and their cloud destinationSAP also introduced new agent-led transformation tooling that can reduce ERP migration efforts by more than 35 percent, driving faster and more predictable projects by automating system analysis, code remediation, configuration and testing at scale.Lastly, SAP announced a full slate of strategic partnerships across each category:- Platform and suite partnerships include Anthropic, with Claude among the foundation models SAP’s AI platform will leverage to power Joule agents across HR, procurement and supply chain; Amazon Web Services, bringing zero-copy data integration between SAP Business Data Cloud and Amazon Athena; Google Cloud and Microsoft, enabling bidirectional agent-to-agent interoperability between Joule and external agent frameworks; Mistral AI and Cohere, delivering sovereign model options on SAP’s cloud infrastructure; n8n, providing visual AI workflow orchestration inside Joule Studio; NVIDIA, whose OpenShell provides the trusted secure runtime for Joule Studio; and Parloa, bringing AI agents into SAP Service Cloud to handle customer interactions with full access to business data and service processes.- Implementation partnerships include Palantir and Accenture, partnering on complex data migration scenarios, and Conduct for AI-powered cloud ERP migrations.Learn more in the SAP Sapphire 2026 Innovation News Guide.Visit the SAP News Center. Get SAP news via LinkedIn and Bluesky.Photo download: https://bit.ly/42zNb5hAbout SAPAs a global leader in enterprise applications and Business AI, SAP (NYSE: SAP) stands at the nexus of business and technology. For over 50 years, organizations have trusted SAP to bring out their best by uniting business-critical operations spanning finance, procurement, HR, supply chain, and customer experience. For more information, visit www.sap.com/hk.For more information, press only:Strategic Public Relations Group (SPRG)Andico TsuiEmail: andico.tsui@sprg.com.hkTel: 2114 4346 / 6902 3831 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com